RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New 'Four-in-One' antibody takes on Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial is testing a new drug called GNC-035, a special antibody that targets four different signals on cancer cells. It is being given to 33 adults with blood cancers like lymphoma or leukemia that have come back or not responded to other treatments. The main goal…
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New 'Quad-Specific' antibody tackles tough leukemia
Disease control OngoingThis early-phase trial is testing a new drug called GNC-035, a tetra-specific antibody, in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and other blood cancers. The study aims to find a safe dose and check for side effects. Only 3 participants have been e…
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC